Search Results - "Méndez‐Vidal, María J."

Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer by Smith, Matthew R, Hussain, Maha, Saad, Fred, Fizazi, Karim, Sternberg, Cora N, Crawford, E. David, Kopyltsov, Evgeny, Park, Chandler H, Alekseev, Boris, Montesa-Pino, Álvaro, Ye, Dingwei, Parnis, Francis, Cruz, Felipe, Tammela, Teuvo L.J, Suzuki, Hiroyoshi, Utriainen, Tapio, Fu, Cheng, Uemura, Motohide, Méndez-Vidal, María J, Maughan, Benjamin L, Joensuu, Heikki, Thiele, Silke, Li, Rui, Kuss, Iris, Tombal, Bertrand

“…Standard therapy for metastatic, hormone-sensitive prostate cancer is androgen-deprivation therapy, usually with docetaxel. A large, multinational, phase 3…”
Get full text

A correlative biomarker study and integrative prognostic model in chemotherapy‐naïve metastatic castration‐resistant prostate cancer treated with enzalutamide by Fernandez‐Perez, María P., Perez‐Navarro, Enrique, Alonso‐Gordoa, Teresa, Conteduca, Vicenza, Font, Albert, Vázquez‐Estévez, Sergio, González‐del‐Alba, Aránzazu, Wetterskog, Daniel, Antonarakis, Emmanuel S., Mellado, Begona, Fernandez‐Calvo, Ovidio, Méndez‐Vidal, María J., Climent, Miguel A., Duran, Ignacio, Gallardo, Enrique, Rodriguez Sanchez, Angel, Santander, Carmen, Sáez, Maria I., Puente, Javier, Tudela, Julian, Martínez, Alberto, López‐Andreo, Maria J., Padilla, José, Lozano, Rebeca, Hervas, David, Luo, Jun, Giorgi, Ugo, Castellano, Daniel, Attard, Gerhardt, Grande, Enrique, Gonzalez‐Billalabeitia, Enrique

“…Background There is a considerable need to incorporate biomarkers of resistance to new antiandrogen agents in the management of castration‐resistant prostate…”
Get full text

Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study by Pinto, Álvaro, Reig, Oscar, Iglesias, Clara, Gallardo, Enrique, García-del Muro, Xavier, Alonso, Teresa, Anguera, Georgia, Suárez, Cristina, Muñoz-Langa, José, Villalobos-León, Laura, Rodríguez-Sánchez, Ángel, Lainez, Nuria, Martínez-Ortega, Esther, Campayo, Marc, Velastegui, Alejandro, Rodriguez-Vida, Alejo, Villa-Guzmán, José C., Méndez-Vidal, Maria J., Rubio, Gustavo, García, Iciar, Capdevila, Laia, Lambea, Julio, Vázquez, Sergio, Fernández, Ovidio, Hernando-Polo, Susana, Cerezo, Sara, Santander, Carmen, García-Marrero, Rosa, Zambrana, Francisco, González-del Alba, Aranzazu, Lazaro-Quintela, Martin, Castellano, Daniel, Chirivella, Isabel, Anido, Urbano, Viana, Antonio, García, Arancha, Sotelo, Miguel, Arévalo, María Garrido, García-Donas, Jesús, Hernández, Carolina, Bolós, M. Victoria, Llinares, Julia, Climent, Miguel A.

“…Axitinib monotherapy obtained approval in pre-treated mRCC patients and recently in combination with pembrolizumab or avelumab in the first-line setting…”
Get full text

Radium-223 for patients with metastatic castration-resistant prostate cancer with asymptomatic bone metastases progressing on first-line abiraterone acetate or enzalutamide: A single-arm phase II trial by Carles, Joan, Alonso-Gordoa, Teresa, Mellado, Begoña, Méndez-Vidal, María J., Vázquez, Sergio, González-del-Alba, Aránzazu, Piulats, Josep M., Borrega, Pablo, Gallardo, Enrique, Morales-Barrera, Rafael, Paredes, Pilar, Reig, Oscar, Garcías de España, Carmen, Collado, Ricardo, Bonfill, Teresa, Suárez, Cristina, Sampayo-Cordero, Miguel, Malfettone, Andrea, Garde, Javier

“…The paper aims to evaluate the efficacy and safety of 223Ra in patients who progressed after first-line androgen deprivation therapy. EXCAAPE (NCT03002220) was…”
Get full text

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma by Motzer, Robert, Alekseev, Boris, Rha, Sun-Young, Porta, Camillo, Eto, Masatoshi, Powles, Thomas, Grünwald, Viktor, Hutson, Thomas E., Kopyltsov, Evgeny, Méndez-Vidal, María J., Kozlov, Vadim, Alyasova, Anna, Hong, Sung-Hoo, Kapoor, Anil, Alonso Gordoa, Teresa, Merchan, Jaime R., Winquist, Eric, Maroto, Pablo, Goh, Jeffrey C., Kim, Miso, Gurney, Howard, Patel, Vijay, Peer, Avivit, Procopio, Giuseppe, Takagi, Toshio, Melichar, Bohuslav, Rolland, Frederic, De Giorgi, Ugo, Wong, Shirley, Bedke, Jens, Schmidinger, Manuela, Dutcus, Corina E., Smith, Alan D., Dutta, Lea, Mody, Kalgi, Perini, Rodolfo F., Xing, Dongyuan, Choueiri, Toni K.

Get full text

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma by Motzer, Robert, Alekseev, Boris, Rha, Sun-Young, Porta, Camillo, Eto, Masatoshi, Powles, Thomas, Grünwald, Viktor, Hutson, Thomas E, Kopyltsov, Evgeny, Méndez-Vidal, María J, Kozlov, Vadim, Alyasova, Anna, Hong, Sung-Hoo, Kapoor, Anil, Alonso Gordoa, Teresa, Merchan, Jaime R, Winquist, Eric, Maroto, Pablo, Goh, Jeffrey C, Kim, Miso, Gurney, Howard, Patel, Vijay, Peer, Avivit, Procopio, Giuseppe, Takagi, Toshio, Melichar, Bohuslav, Rolland, Frederic, De Giorgi, Ugo, Wong, Shirley, Bedke, Jens, Schmidinger, Manuela, Dutcus, Corina E, Smith, Alan D, Dutta, Lea, Mody, Kalgi, Perini, Rodolfo F, Xing, Dongyuan, Choueiri, Toni K

“…Lenvatinib plus either pembrolizumab or everolimus was compared with sunitinib as first-line therapy for advanced renal cell cancer. Progression-free survival…”
Get full text

Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial by Szabados, Bernadett, Rodriguez-Vida, Alejo, Durán, Ignacio, Crabb, Simon J., Van Der Heijden, Michiel S., Pous, Albert Font, Gravis, Gwenaelle, Herranz, Urbano Anido, Protheroe, Andrew, Ravaud, Alain, Maillet, Denis, Mendez-Vidal, Maria J., Suárez, Cristina, Linch, Mark, Prendergast, Aaron, Tyson, Charlotte, Mousa, Kelly, Castellano, Daniel, Powles, Thomas

“…There are limited data on toxicity and surgical safety associated with neoadjuvant programmed death ligand 1 (PD-L1) inhibitors prior to radical cystectomy…”
Get full text

Cardiac tumors. Experience with two cases by García Martínez, E, Torres Borrego, J, Méndez Vidal, Maria J, Beaudoin Perron, A, Peña Rosa, Maria J

“…Cardiac tumors are rare neoplasms with an incidence of 0.027 cases per 100. Up to 90 % of these tumors are benign but, because of their location, they can be…”
Get full text

Evaluation of an automated wavelet-based system dedicated to the detection of clustered microcalcifications in digital mammograms by LADO, Maria J, TAHOCES, Pablo G, MENDEZ, Arturo J, SOUTO, Miguel, VIDAL, Juan J

“…Mammographic screening programs are delivering reductions in breast cancer mortality. However, breast cancer screening will be cost effective and will provide…”
Get full text